Co-investors sought for Biotech with commercialised infection prevention products for pre-listing funding


Published on: 12th October 2023

Timeline expectations: In the next 3 months


Official STAK Submissions » Other Profession


day left

Open to bids

Deal value


**Sophisticated investors only, enquiries via members please** Firm is the only company in the world to have registered a patent on a finished Hypochlorous Acid (HOCL) product, removing the need for alcohol-based sanitising products. They have created a formulation that not only has excellent shelf life but additionally maintains efficacy in the presence of serum (blood, saliva, dirt etc).
Up to £5m capital is currently being raised at a pre-money valuation of £58m (EIS shares and/or (ii) non-EIS convertible debt investment). This represents a 71% discount to the initial listing valuation of >£200m targeted by management at the Company’s planned IPO on the London Stock Exchange. To date >£14m invested in development of licensed technology into commercially viable products that meet an unmet public health need (funds raised via CLN) Two non-alcohol sanitising products already commercial, in active use in NHS. **Sophisticated/ Professional Investors ONLY** **Further details available within, verified members only**


Beneficiary net worth -